The US Food and Drug Administration (FDA) has set a target goal date of 7 October 2019 for Pfenex’ PF708 proposed follow-on version of Eli Lilly’s Forteo (teriparatide) after accepting the company’s 505(b)(2) new drug application (NDA).
With this step, chief executive officer Eef Schimmelpennink observed, “We believe PF708 remains on track to enter the US market...








